Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Catenin delta-1 (CTNND1) encodes the protein p120-catenin, a member of the armadillo repeat-containing catenin family. p120-catenin interacts directly with classical cadherins (especially E-cadherin, CDH1) and is vital to the stability of cell-cell adhesion complexes in epithelial and mesenchymal tissues. It prevents endocytosis and premature degradation of cadherins, thereby maintaining adherens junctions. By functioning as a scaffolding protein, p120-catenin recruits and regulates RhoA GTPase, modulating actin cytoskeleton dynamics and cell motility. It also participates in signaling pathways that regulate gene expression and cell differentiation, including indirect modulation of NF-κB and Kaiso/Wnt transcription factors. CTNND1 is essential for normal craniofacial development, heart formation, and tissue differentiation, and genetic mutations cause human developmental syndromes such as blepharocheilodontic syndrome and cleft palate. The protein has multiple isoforms, with tissue-specific expression patterns detected in epithelial, mesenchymal, neural, and cardiac cells. If used in research, CTNND1 is best classified as a developmental and structural regulator rather than a classic receptor, enzyme, or transporter. It is implicated in disease primarily via genetic defects or dysregulation in cancer, rather than as a conventional pharmacologic target.
Not applicable; no drugs directly target CTNND1. Indirectly altered via regulatory or pathway-based interventions (e.g., targeting the cadherin/catenin signaling axis in cancer research), but not by selective drugs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Catenin delta-1 (CTNND1).